Richard Carey, NP
Family · Nashua, NHNPI 1881820355
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $43,198 of the $51,134 with a category attached, or 84.5%. AbbVie accounts for 83.8% of it on its own, with 18 other manufacturers making up the rest. Among family clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 389 payments — averaging $131.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$43K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$6K
- Sunovion Pharmaceuticals Inc.$1K
- Alkermes, Inc.$186
- Neos Therapeutics, LP$182
- Axsome Therapeutics, Inc.$180
- plus $804 from 13 others
What the payments were for
- Speaking & faculty fees$43,19884%
- Travel & lodging$1,9394%
- Food & beverage$5,96412%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 278 | $42,866 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $5,748 |
| Sunovion Pharmaceuticals Inc. | 24 | $1,168 |
| Alkermes, Inc. | 11 | $186 |
| Neos Therapeutics, LP | 10 | $182 |
| Axsome Therapeutics, Inc. | 4 | $180 |
| Lundbeck LLC | 7 | $139 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $112 |
| Corium, LLC | 4 | $85 |
| Bausch Health US, LLC | 4 | $77 |
| Ironshore Pharmaceuticals Inc. | 3 | $63 |
| Collegium Pharmaceutical, Inc. | 3 | $61 |
| Teva Pharmaceuticals USA, Inc. | 2 | $59 |
| Supernus Pharmaceuticals, Inc. | 2 | $58 |
| Eisai Inc. | 3 | $55 |
| Idorsia Pharmaceuticals US Inc | 2 | $43 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$51,134 in reported general payments places this provider in the 95th percentile of 713 family providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 47 | $67,752 |
| VyvanseLisdexamfetamine Dimesylate | 31 | $29,731 |
| TrintellixVortioxetine Hydrobromide | 31 | $14,757 |
| Lurasidone Hcl | 13 | $9,427 |
| LexaproEscitalopram Oxalate | 22 | $9,174 |
| DayvigoLemborexant | 18 | $6,349 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 42 | $4,727 |
| Alprazolam ErAlprazolam | 26 | $4,146 |
| Vilazodone Hcl | 26 | $3,204 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 93 | $2,738 |
| Bupropion XlBupropion Hcl | 78 | $2,453 |
| Aripiprazole | 55 | $2,423 |
| Trazodone Hcl | 72 | $2,410 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 35 | $2,291 |
| Methylphenidate ErMethylphenidate Hcl | 26 | $2,156 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Lexapro | $42,866 | $76,92669 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $112 | $44,48862 claims |
| Eisai Inc.Dayvigo | $55 | $6,34918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 713 family providers in New Hampshire.
Other family in Nashua
- Megan RicardNashua$7K
- Rachel DavisNashua$2K
- Tara Delle ChiaieHampton$548K
- Wendy WrightAmherst$447K
- Summer BellDerry$16K
- Laura HudsonDover$14K
- Debra KrisonNorth Hampton$13K
- Michelle WhiteBedford$9K
- Brant OliverConcord$9K
- Cassandra CavanaughDover$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.